Bladder cancer kills 15,000 annually and because of few therapeutic advances there is a need for innovation. This project has discovered suppressors of bladder tumor growth and metastasis and shown that low expression of AGL, an enzyme involved in glycogenolysis, and RhoGDI2, an inhibitor of multiple GTPases, is associated with cancer recurrence and death. The Goal of this continuation project is to understand how reduced AGL levels result in aggressive bladder cancer and to translate this knowledge into novel therapies. We found bladder cancer cells with low AGL express elevated levels of Hyaluronic Acid (HA) synthase 2 (HAS2), and its extracellular product HA, and have activated RhoC and Rac1, known drivers of tumor progression. We demonstrated RhoC/Rac1 activity is suppressed by RhoGDI2, linking the actions of the two metastasis suppressors. Cells with low AGL also exhibit increased glycolysis, glucose import and autophagy. When either glucose import or autophagy are blocked, low AGL tumor cells show greater reduction of in vitro growth than cells with higher AGL levels, exposing a vulnerability of these aggressive cells. These data support an innovative Hypothesis: Tumor cells with low AGL generate growth and metastatic signals via production of HA, activation of its receptors CD44 and RHAMM, and downstream effectors such as RhoC and Rac1. For these signals to be actualized, sufficient energy needs to be provided via enhanced glucose import and autophagy.
Three Specific Aims will test this hypothesis. 1) Evaluate impact of HA signaling on aggressiveness of bladder cancers with low AGL. We will determine if HA drives tumor progression via its receptors CD44 and RHAMM and effectors RhoC and Rac1 that are inhibited by RhoGDI2. Experiments will use RNAi and receptor inhibition in human xenografts. 2) Determine role of the AGL signaling network in bladder cancer development and progression. We will evaluate the independent predictive value of tumor suppressor genes and components of the AGL signaling network in a large panel of annotated human tumors, to define a predictive multigene biomarker signature and possible new therapeutic targets. We will use full and conditional (bladder urothelium) AGL knockout mice in a chemical carcinogenesis model that generates spontaneous visceral metastases to test whether lack of AGL makes urothelium more susceptible to carcinogenesis and resulting tumors more aggressive. 3) Target molecular vulnerabilities of bladder cancers with low AGL expression. Here we test whether blocking glucose import and/or autophagy reduces in vivo bladder tumor growth. We will use shRNA and pharmacologic agents already in preclinical/clinical testing. We will screen shRNA libraries to metabolic and autophagy genes in cells with low AGL to discover novel genes essential to the aggressive tumor phenotype, with the expectation that some of these will become therapeutic targets. We will evaluate combined inhibition of HA signaling and energy production pathways with the expectation this will have synergistic detrimental effects on tumor progression. Impact: This project will lay the foundation for future biomarker-driven personalized clinical trials that target critical vulnerabilities in bldder cancer while informing us on how AGL executes its unanticipated role in cancer.

Public Health Relevance

In the US, ~50,000 patients/yr are diagnosed and ~15,000 die of bladder cancer but unfortunately, disproportionately few research resources are targeted to this disease by the federal government and philanthropic organizations. Overall, half a million Americans live with bladder cancer, with a cost per patient from diagnosis to death of ~$150K, the greatest of any cancer in Medicare. Furthermore, the death rate from this disease has remained relatively unchanged for 30 years. To identify new and functionally relevant pathways that can be therapeutically targeted in bladder cancer, we used a new genomic shRNA screen and identified Amylo- Alpha-1, 6-Glucosidase, 4-Alpha-Glucanotransferase (AGL), an enzyme involved in conversion of glycogen to glucose, as a new bladder tumor growth suppressor. This was the first description of a role for this gene in human cancer. In bladder cancer, AGL expression is lower in metastatic disease and patients with localized invasive disease and low tumor AGL expression generally recur and die. Our goal here is to understand how AGL works and use this knowhow to develop novel predictors of tumor recurrence and treatments that reduce the death rate from this cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA143971-10
Application #
9987534
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Woodhouse, Elizabeth
Project Start
2018-08-08
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
10
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Duex, Jason E; Swain, Kalin E; Dancik, Garrett M et al. (2018) Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. Mol Cancer Res 16:69-77
Duex, Jason E; Owens, Charles; Chauca-Diaz, Ana et al. (2017) Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis. Cancer Res 77:4858-4867
Nickerson, M L; Witte, N; Im, K M et al. (2017) Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene 36:35-46
Ngo, Anh T P; Thierheimer, Marisa L D; Babur, Özgün et al. (2017) Assessment of roles for the Rho-specific guanine nucleotide dissociation inhibitor Ly-GDI in platelet function: a spatial systems approach. Am J Physiol Cell Physiol 312:C527-C536
Guin, Sunny; Ru, Yuanbin; Agarwal, Neeraj et al. (2016) Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis. Clin Cancer Res 22:1274-83
Sottnik, Joseph L; Theodorescu, Dan (2016) CD44: A metastasis driver and therapeutic target. Oncoscience 3:320-321
Ahmed, Mansoor; Sottnik, Joseph L; Dancik, Garrett M et al. (2016) An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. Cancer Cell 30:432-443
Oldenburg, Darby; Ru, Yuanbin; Weinhaus, Benjamin et al. (2016) CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL). BMC Cancer 16:713
Marie, Chelsea; Verkerke, Hans P; Theodorescu, Dan et al. (2015) A whole-genome RNAi screen uncovers a novel role for human potassium channels in cell killing by the parasite Entamoeba histolytica. Sci Rep 5:13613
Griner, Erin M; Dancik, Garrett M; Costello, James C et al. (2015) RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Mol Cancer Res 13:483-92

Showing the most recent 10 out of 34 publications